CPT® Code 90621

The CPT® Code 90621 refers to the meningococcal recombinant lipoprotein vaccine, specifically targeting serogroup B (MenB-FHbp). This vaccine is designed for intramuscular administration and is indicated for individuals aged 10 years and older. The primary purpose of this vaccine is to prevent infections caused by the bacterium Neisseria meningitidis serogroup B, which is known to be a significant cause of meningitis and sepsis. The N. meningitidis serogroup B bacterium is prevalent globally and is transmitted through respiratory droplets and oral secretions, such as those exchanged during coughing, kissing, or sharing food and utensils. Infection with this bacterium can lead to severe health complications, including meningitis, which is an inflammation of the protective membranes covering the brain and spinal cord, and sepsis, a life-threatening response to infection that can result in organ failure. The consequences of such infections can be dire, potentially leading to fatalities within hours or days, or causing long-term disabilities such as hearing loss, cognitive impairments, and limb amputations. The CPT® Code 90621 is part of a broader classification of vaccines, which includes other codes such as 90620, which reports the meningococcal recombinant protein and outer membrane vesicle vaccine (MenB-4C) administered on a two-dose schedule. In contrast, the MenB-FHbp vaccine (CPT® Code 90621) can be administered in either a two or three-dose schedule, typically at intervals of 0, 2, and 6 months. It is important to note that these codes specifically report the vaccine supply, while the administration of the vaccine is billed separately.